GlassScriptPhysician profile
Tracy M Rosplohowski
NPI 1851707012
$13,636.22
in general payments reported to CMS, 2019-2025
35 companies · $2,807 in 2025
The $2,807 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,291 · 2022: $2,701 · 2023: $2,949 · 2024: $2,889 · 2025: $2,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,254 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,253.55 |
| Education | $391.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,070.15 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,142.84 | 2021-2025 | Sotyktu |
| Janssen Biotech, INC. | $1,068.46 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,055.89 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $949.04 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $688.76 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $660.10 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $658.23 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Allergan, INC. | $637.18 | 2021-2022 | |
| Lilly USA, LLC | $466.82 | 2021-2025 | Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $456.75 | 2021-2025 | |
| Amgen INC. | $425.31 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $417.86 | 2021-2025 | Opzelura |
| Pfizer INC. | $333.47 | 2021-2025 | |
| Leo Pharma INC. | $239.35 | 2021-2025 | Adbry |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $193.12 | 2021-2024 | Jublia, Cabtreo |
| Arcutis Biotherapeutics, INC. | $191.90 | 2023-2025 | Zoryve |
| Biofrontera INC. | $179.46 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $153.57 | 2021 | |
| Dermavant Sciences, INC. | $106.67 | 2022-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $101.04 | 2024 | Tremfya |
| Journey Medical Corporation | $71.43 | 2021-2023 | |
| Lnhc, INC | $60.26 | 2025 | Zelsuvmi |
| Almirall LLC | $43.37 | 2021-2023 | Seysara |
| Epi Health, LLC | $41.91 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.49 | 2024 | Spevigo, Cyltezo |
| Verrica Pharmaceuticals INC. | $39.13 | 2024-2025 | Ycanth |
| Blueprint Medicines Corporation | $27.56 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $21.89 | 2022 | |
| Botanix Sb INC | $20.52 | 2025 | Sofdra |
| Merz North America, INC. | $18.04 | 2023 | Xeomin |
| Krystal Biotech INC | $16.30 | 2025 | Vyjuvek |
| Mayne Pharma Commercial LLC | $15.80 | 2022 | |
| Genentech USA, INC. | $14.88 | 2021 | |
| Organon LLC | $9.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Rosplohowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.